查看购物车
  • Traditional Chinese
  • English
  • Japanese
基因改造动物模型市场—全球及区域分析：按技术、动物类型、应用、最终用户和地区划分—分析与预测（2025-2035）
市场调查报告书
商品编码
1927582

基因改造动物模型市场—全球及区域分析：按技术、动物类型、应用、最终用户和地区划分—分析与预测（2025-2035）

Transgenic Animal Model Market - A Global and Regional Analysis: Focus on Technology, Animal Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 164 Pages | 商品交期: 1-5个工作天内

价格

受基因工程技术的进步和对严格的临床前测试日益增长的需求的推动，基因改造动物模型市场正在经历显着增长。

基因改造动物，即用其他物种的基因改造的动物，对于研究人类疾病、测试新治疗方法和改进农业技术至关重要。这些模型使研究人员能够模拟人类疾病，从而深入了解疾病机制、遗传易感性和潜在治疗方法的有效性。

关键市场统计数据
预测期 2025-2035
2025 年评估 27.96亿美元
2035 年预测 67.993亿美元
复合年增长率 9.29%

随着精准医学领域的发展，基因改造模型在推动个人化医疗方面发挥着至关重要的作用。这些模型使研究人员能够研究基因对癌症、遗传性疾病和慢性病的影响，有助于开发更具针对性和更有效的治疗方法。随着CRISPR-Cas9等基因编辑技术的兴起，对这些模型的需求日益增长，从而支持开发针对个体基因组成量身定制的治疗方法。将这些先进模型整合到研究中，不仅可以加速药物研发，还可以透过减少治疗中的试验过程来改善病患的治疗效果。

市场概览

全球基因改造动物模型市场预计将迎来显着成长，到2035年市场规模预计将达到67.993亿美元。基因工程技术的进步以及对更精准的临床前测试需求的不断增长，推动了基因改造动物模型市场的蓬勃发展。基因改造动物模型是透过将外源基因插入生物体基因组而建构的，在理解复杂疾病和检验新治疗方法发挥关键作用。这些模型使研究人员能够重现人类疾病，并深入了解疾病机制、遗传影响以及各种治疗方法的有效性。

对个人化医疗日益增长的需求正在推动基因改造模型的应用，这些模型能够帮助我们更深入地了解遗传因素如何影响个体的疾病感受性和治疗反应。 CRISPR 和次世代定序(NGS) 等技术透过实现更精准的基因修饰和促进建构更精确、更接近人类的模型，加速了这些模型的开发。这在肿瘤学、神经病学和遗传疾病等领域尤其重要，因为在这些领域，个人化治疗的重要性日益凸显。

此外，人工智慧 (AI) 和巨量资料分析的融合正在改变基因改造模型在研究中的应用方式。这些技术透过预测疾病预后、优化治疗策略以及提高动物模型的精确度，提升了药物研发的效率。随着这些技术的不断发展，它们将进一步推动基因改造动物模型市场的创新，从而实现更个人化和有效的治疗方案。然而，伦理问题、监管复杂性以及建构和维护这些模型的高成本等挑战仍然限制市场成长。儘管存在这些障碍，基因编辑技术和计算工具的持续进步有望在未来推动市场扩张。

对产业的影响

基因改造动物模型透过推进药物发现和开发，对生物技术和製药产业产生了深远的影响。例如，基因转殖小鼠在阿兹海默症研究中的应用，为深入了解疾病的遗传基础提供了宝贵的见解，并促成了潜在治疗方法的测试，例如靶向β-淀粉样蛋白的药物AduHerm。这些模型使研究人员能够精确地模拟人类疾病，从而实现更有效的临床前试验。

基因工程模型正在提高临床试验的可预测性和效率。例如，携带人类癌症基因的基因工程小鼠被用于测试免疫疗法，例如用于治疗白血病的CAR-T疗法Kymriah。透过模拟人体反应，这些模型降低了后期临床试验失败的风险。

CRISPR 技术的应用使得基因改造动物模型的开发成为可能，从而可以进行精确的基因编辑，尤其是在镰状细胞疾病相关调查中。利用基因转殖小鼠进行的基因治疗试验已经开展，为 CTX001 等治疗方法提供了途径，目前正在进行临床试验。

整体而言，基因改造模型正在加速精准医疗，提高治疗效果，优化临床试验，进而实现更快、更有经济的药物研发。

市场区隔:

细分 1：按技术

  • CRISPR/Cas9
  • 显微注射
  • 胚胎干细胞注射
  • 其他的

截至2024年，CRISPR/Cas9技术在全球基因改造动物模型市场中占最大份额，达到44.96%。 CRISPR/Cas9技术凭藉其基因修饰的精准性、高效性和多功能性，彻底革新了基因改造动物模型市场。与传统方法不同，CRISPR技术能够精确地在基因组的特定位置进行基因敲入、敲除和编辑，使其成为更快、更准确、更经济高效的方法。这大大加速了用于疾病研究、药物研发和个人化医疗的动物模型的建构。例如，CRISPR技术已成功应用于建构模拟癌症、遗传疾病和神经退化性疾病等复杂疾病的基因修饰小鼠模型，这些模型被用于测试标靶治疗和基因编辑疗法。

CRISPR/Cas9市场的快速成长得益于其能够以比传统方法更低的成本和更短的时间建立复杂的动物模型。其应用领域正在不断扩展，涵盖基因治疗、癌症研究和个人化医疗等领域，许多公司和研究机构正利用CRISPR技术建构更精准的模型，用于药物测试和治疗方法的开发。随着技术的进步，精准度和递送方式的不断改进，CRISPR有望进一步加速生物医学创新，并成为基因研究的关键工具。这将使其成为基因改造动物模型市场中成长最快的细分领域。

第二部分：依动物类型

  • 囓齿动物（小鼠和大鼠）
  • 兔子
  • 猪
  • 其他的

按动物类型划分，全球基因改造动物模型市场以囓齿类动物为主导，预计到2024年将占74.96%的市场。囓齿类动物，尤其是小鼠，在基因改造动物模型市场中占据主导地位，占生物医学研究中使用的基因改造动物的95%以上。小鼠之所以成为首选模式生物，是因为它们具有几个关键优势：可以对其完整的基因组序列进行广泛分析，并且与人类具有高度的遗传相似性。这些因素使它们成为研究人类疾病、遗传失调和药物反应的理想模型。例如，基因转殖小鼠被广泛用于建立阿兹海默症模型，从而可以研究淀粉样斑块并测试诸如Aduherm等旨在减少斑块累积的治疗方法。小鼠也被广泛用于癌症研究，例如敲除p53等基因可以建构模拟人类肿瘤生长的模型，有助于评估CAR-T细胞疗法等治疗方法。

囓齿类基因改造动物模型市场的成长主要得益于小鼠能够精准操控基因，并藉助先进技术的支持，使研究人员能够高精度地模拟人类疾病。此外，小鼠繁殖週期短、易于进行生理和行为测试，且能适应受控的实验环境，使其成为大规模研究的理想选择。这些特性，加上小鼠在癌症、神经退化性疾病疾病和代谢性疾病研究中的既有地位，确保了小鼠在基因改造动物模型市场中持续占据主导地位并保持快速增长。

细分 3：按应用

  • 药物发现与开发
  • 疾病研究
  • 基因功能研究
  • 毒理学和安全性测试
  • 其他的

按应用领域划分，药物发现与开发领域将主导全球基因改造动物模型市场，预计2024年将占据54.19%的市场。这是因为该领域是使用这些模型进行临床前研究的主要用户，涵盖从标靶检验和作用机制研究到疗效筛检和早期安全性评估等各个环节。製药公司和领先的生物技术公司不断增加对基因改造和人源化模型的预算投入，尤其是在肿瘤学、代谢性疾病、神经退化性疾病以及先进治疗方法（免疫肿瘤学、基因和细胞疗法）等领域，因为这些模型能够提高转化相关性并降低后期研发失败的风险。此外，该领域的研究量庞大，需要持续获得授权或客製化培育的品系，从而导致持续的支出。与製药研发管线对接的合约研究组织（CRO）提供的基因改造模型服务进一步简化了实施流程，并增强了市场需求。因此，药物发现与开发领域仍是该市场最大且最具商业性价值的需求来源。

细分 4：按最终用户

  • 製药和生物技术公司
  • 学术和研究机构
  • 受託研究机构（CRO）

以终端用户类型划分，製药和生物技术公司在全球基因改造动物模型市场中占据主导地位，2024年市占率达57.38%。製药和生物技术公司是基因改造动物模型的主要需求来源，其研发活动推动了市场扩张。这些机构依赖基因工程动物来降低研发风险，检验药物标靶，阐明疾病通路，产生疗效和安全性数据，并在首次人体临床试验前优化给药方案。例如，在肿瘤学领域，人源化基因转殖小鼠常用于评估免疫肿瘤候选药物，而兔子和猪等体型较大的基因转殖动物则用于支持需要类似人类生理功能的心血管和代谢研究。精准医疗、生物製药以及基因和细胞疗法的加速发展加剧了这种需求，因为这些治疗方法通常针对人类特有的通路，而这些通路无法在体外进行充分模拟。同时，大型製药公司正委託开发客製化的基因改造品系，以模拟罕见疾病、多因子疾病和儿童疾病，从而提高临床成功率，并满足监管机构对疾病相关临床前数据的要求。先进技术的取得、对转化可靠数据的需求以及日益严格的监管审查，共同推动了製药和生物技术公司成为基因改造动物模型市场成长和创新的核心驱动力。

细分5：按地区

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 澳洲
    • 韩国
    • 其他的
  • 其他地区

北美凭藉着多项结构性优势，在基因改造动物模型市场占据主导地位。该地区拥有全球最高的生物製药研发活动密度，并拥有健全的法规环境，有利于创新。美国和加拿大的众多製药和生物技术公司正在推进肿瘤、感染疾病和代谢性疾病等关键治疗领域的高通量临床前研发管线。在这些领域，基因改造和人源化动物模型对于在临床试验前获得可靠的体内数据至关重要。美国食品药物管理局（FDA）和加拿大卫生署等监管机构积极参与新兴治疗方法，例如mRNA疗法、个人化癌症疫苗和呼吸道合胞病毒（RSV）疫苗，从而推动了对符合严格证据标准的高预测性动物模型的需求。此外，北美在生产基础设施、自动化和符合GMP规范的工作流程方面的投资也延伸至临床前运营，从而能够快速创建和部署定制的转基因品系，包括疾病特异性和人源化模型。

该地区慢性病高发，加上精准医疗和细胞基因疗法的早期应用，推动了对能够重现人类生物学路径的动物模型的需求。此外，北美拥有雄厚的财力、密集的受託研究机构（CRO）生态系统，以及主导机构对高品质数据的需求，这些因素共同促成了北美成为基因改造动物模型市场的战略中心。

基因改造动物模型市场的最新趋势

  • 2025 年 8 月，Taconic Biosciences 与 Cyagen Biosciences 合作，为临床前研究人员提供更广泛、更有效率的途径，取得 Cyagen 超过 16,000 种基因工程小鼠模型的庞大库。
  • 2025 年 7 月，百奥赛图製药公司宣布对其临床前业务部门进行重大改进，包括扩大基因工程动物模型组合，包括靶向人源化小鼠、免疫人源化小鼠、转基因小鼠和免疫力缺乏小鼠，以及全面的临床前服务，包括疗效测试、PK/PD 分析、生物标记评估和非 GLP 毒理学测试。
  • 2024年10月，Alloy Therapeutics与史克里普斯研究所签署了一项机构授权合约，授权其使用ATX-Gx平台。该平台能够生成全人源抗体。这项非独家授权将使史克里普斯研究所的所有研究人员都能使用ATX-Gx平台进行抗体医药品和疫苗的研发。
  • 2024年6月，百奥赛图公司（Biocytogen）的RenLite平台获得美国专利。该平台能够建构具有通用轻链的全人源抗体，从而简化双特异性抗体和抗体药物偶联物（ADC）的开发。这项创新技术提高了抗体的多样性，并简化了CMC製程。

需求——驱动因素、挑战与机会

市场需求驱动因素：医药研发活动增加

对药物研发日益重视是基因改造动物模型市场的主要驱动力。随着产业朝着更具针对性和更有效的治疗方法发展，对基因改造动物的需求显着增长。这些基因改造模型对于应对现代药物研发的复杂性至关重要，尤其是在个人化医疗和精准治疗等领域。基因改造动物能够模拟人类疾病的生物学特性，使研究人员能够在与人类疾病环境高度相似的环境中测试治疗方法。例如，在爱滋病研究中，研究人员会使用人源化小鼠来评估抗逆转录病毒药物在临床试验前的疗效。

随着製药业不断推进药物研发，提高药物发现的速度和精准度，对能够预测人体反应的模型的需求也日益增长。基因改造动物模型对于研究传统模型无法重现的疾病至关重要，例如癌症、神经退化性疾病疾病和心血管疾病。例如，p53基因敲除小鼠被用于癌症研究，以探讨肿瘤进展并测试靶向突变基因的治疗方法；而表达人类Tau蛋白的转基因小鼠则在阿兹海默症研究中发挥重要作用。对创新药物和生物製药研发投入的不断增加，进一步推动了对这些模型的需求，这些模型对于理解疾病机制、测试新型化合物以及评估治疗方法的安全性和有效性至关重要。

市场挑战－动物模型的高昂维修成本

基因改造动物模型市场面临的一大挑战是高昂的维修成本。从育种到实验应用，开发和维护这些模型都需要在各个阶段投入大量资金。饲养这些动物需要专门的环境控制设施，与传统模型相比，这会增加资本和营运成本。基因改造动物需要先进的基因工程技术、持续监测，通常需要多代育种，这导致开发週期延长，并增加了遗传学家和兽医等专业人员的劳动力成本。

例如，仅购买C57BL/6近交系小鼠的成本可能超过3500美元，这还不包括笼具维护、兽医护理以及显微注射和胚胎移植等特殊操作的费用。这些基因改造动物需要无菌环境和特殊护理，进一步增加了持续营运成本。虽然杂交品係可以降低部分成本，但建造和维护基因改造模型的总体成本仍然是小规模实验室和Start-Ups企业的一大障碍，限制了市场成长。

因此，像辉瑞和诺华这样的大型製药公司能够承担高成本，而规模较小的生物技术公司和学术实验室则被迫依赖细胞分析和电脑模拟等替代模型。这种资金壁垒减缓了市场扩张，尤其对规模较小的参与企业而言更是如此。

市场机会－CRISPR技术在生物医学研究中的崛起

CRISPR技术的出现彻底改变了生物医学研究中基因改造动物模型的建构和效用，实现了快速、精准、高效的基因组编辑。 CRISPR/Cas9技术使研究人员能够以远高于传统方法（例如胚胎干细胞同源重组）的精度和成本效益，在从小鼠到猪、羊、鸡等大型动物的各种动物中构建靶向基因敲除、敲入和点突变模型。 CRISPR加速了大小动物疾病模型的构建，这些模型能够忠实地模拟人类病理，包括神经退化性疾病、心血管疾病、囊肿纤维化和癌症。这些模型能够更可靠地帮助阐明疾病机制和筛检治疗方法。此外，CRISPR技术还能够进行复杂的基因操作，包括同时编辑多个基因，从而建立多基因疾病模型并研究基因交互作用。

CRISPR 将促进生物反应器动物的生产，例如基因工程改造的鸡可以在鸡蛋中生产药用蛋白，或者基因工程改造的动物可以生产抗体，从而扩大工业和治疗应用，并能够开发具有抗病能力的转基因动物（例如抗病毒家禽），从而支持食品安全和生物医学研究。

除了基因编辑外，CRISPR 还应用于再生医学、组织工程和表观基因编辑，可以在不改变 DNA 序列的情况下调节基因表现，以及基于 CRISPR 的诊断工具，如 SHERLOCK 和 DETECTR，用于快速灵敏地检测病毒感染和基因突变。

市场趋势－个人化医疗需求不断成长

个人化医疗的日益普及显着增加了药物发现和治疗方法开发中对基因改造动物模型（尤其是人源化小鼠）的需求。随着治疗方案越来越贴合个体的基因谱，基因改造模型对于测试基因疗法、免疫疗法和患者特异性药物方案至关重要。透过基因工程改造表达人类基因和突变的人源化小鼠模型，研究人员能够更精确地研究人类疾病，并更有效地预测治疗结果。

这些模型对于基因疗法至关重要，例如反义寡核苷酸（ASO），用于沉默阿兹海默症、亨廷顿舞蹈症和肌萎缩侧索硬化症（ALS）等神经退化性疾病中的有害基因。利用人源化小鼠的成功研究表明，疾病相关基因的表达降低，症状得到改善。此外，将CRISPR/Cas9技术与基因改造模型结合，可实现标靶基因编辑。例如，研究表明，降低ALS小鼠体内hSOD1的水平可以延缓疾病进展，为未来的基因编辑疗法铺平道路。

基因转殖模型在免疫疗法试验中也发挥重要作用，例如CAR-T细胞疗法和标靶人类特异性蛋白的抗体疗法。例如，具有人类免疫系统的人源化小鼠被用于评估癌症和阿兹海默症研究中的免疫反应。同样，透过将人类肿瘤组织移植到小鼠体内而建构的患者来源异种移植模型（PDX模型）有助于评估个人化疗法如何与患者独特的基因组成相适应。

随着个人化医疗的不断发展，基因改造动物模型已成为基因标靶治疗开发的关键，能够更深入地了解人类疾病的多样性，简化药物发现过程，并支持开发更安全、更有效的、针对个别患者的治疗方法。

本报告深入分析了基因改造动物模型的最新技术趋势，使各组织能够推动创新并开发满足市场需求的尖端产品。

透过全面的市场分析和对关键成长机会的识别，我们为企业提供製定有针对性的行销策略和有效扩大市场份额所需的知识。

竞争策略：该报告包含全面的竞争格局分析，以帮助企业了解竞争对手的优势和劣势，并制定有效的策略以获得市场竞争优势。

我们提供有关不断变化的法规结构、核准流程和行业指南的最新信息，以确保您的组织保持合规，并加快新型转基因动物模型产品的市场准入。

投资和业务扩大策略：透过分析市场趋势、资金筹措模式和合作机会，我们帮助企业做出明智的投资决策，并识别潜在的併购机会以促进业务成长。

调查方法

市场设计与检验中的关键考虑因素与假设

  • 计算市场规模的基准年设定为2024年。对2021财年至2023财年期间的历史表现进行了分析。估算了2024财年的市场规模，并对2025财年至2035财年期间的市场规模进行了预测。
  • 本报告的研究范围是基于与全球企业专家的对话而精心製定的。本报告提供关于CRISPR/Cas9、显微注射、胚胎干细胞注射和其他基因改造动物模型技术的市场研究。
  • 各公司的收入均以 2023 财年及 2024 财年的年度报告为依据。对于私人公司，其收入是根据一手调查资讯、资金筹措历史、市场合作和业务表现等因素估算得出的。
  • 本报告基于现有的基因改造动物模型解决方案绘製了市场图。报告中涵盖并介绍了该领域所有提供重要产品和服务的主要企业。

主要市场参与企业及竞争格局概述

我们根据对公司覆盖范围、产品系列和市场渗透率的分析，并结合从行业领先专家那里收集的信息，来选择对其中进行介绍的公司。

该市场的一些主要企业包括：

  • Charles River Laboratories International, Inc.
  • Creative Biolabs
  • Alloy Therapeutics, Inc.
  • Inotiv.
  • HuidaGene
  • genOway
  • Ingenious Targeting Laboratory
  • OmniAb Inc.
  • Taconic Biosciences
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd
  • Merck Group
  • Janvier Group

目录

执行摘要

第一章 全球基因改造动物模型市场：产业展望

  • 市场概览
    • 市场概览与生态系统
  • 市场趋势
    • 影响分析
    • 对个人化医疗的需求日益增长
  • 监管状态
    • 北美洲
    • 欧洲
    • 亚太地区
    • 其他地区
  • 定价分析
    • 产生成本（建立新模型）
    • 购置成本（购买现有型号）
    • 额外费用
  • 技术展望
  • 市场动态
    • 驱动因素、挑战和机会：评估当前和未来的影响
    • 市场驱动因素
    • 市场限制
    • 市场机会

第二章：技术

  • 概述
    • CRISPR/Cas9
    • 显微注射
    • 胚胎干细胞注射
    • 其他的

第三章 动物种类

  • 概述
    • 囓齿动物（小鼠和大鼠）
    • 兔子
    • 猪
    • 其他的

第四章 应用

  • 概述
    • 药物发现与开发
    • 疾病研究
    • 基因功能研究
    • 毒理学和安全性测试
    • 其他的

第五章 最终用户

  • 概述
    • 製药和生物技术公司
    • CRO
    • 学术研究机构

第六章 区域

  • 区域概况
  • 北美洲
    • 区域概览
    • 市场成长驱动因素
    • 成长抑制因素
    • 市场规模及预测
    • 我们
    • 加拿大
  • 欧洲
    • 区域概览
    • 市场成长驱动因素
    • 成长抑制因素
    • 市场规模及预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 区域概览
    • 市场成长驱动因素
    • 成长抑制因素
    • 市场规模及预测
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 其他地区
    • 区域概览
    • 市场成长驱动因素
    • 成长抑制因素
    • 市场规模及预测

第七章 竞争标桿分析与公司概况

  • 关键策略与发展（2023-2025）
  • 公司关键发展分析（2023-2025）
  • 公司简介
    • Charles River Laboratories International, Inc.
    • Creative Biolabs
    • Alloy Therapeutics, Inc.
    • Inotiv.
    • Ingenious Targeting Laboratory.
    • HuidaGene
    • genOway
    • OmniAb, Inc.
    • Taconic Biosciences
    • Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'
    • Sigma-Aldrich Co. (Merck Group)
    • Janvier Group (Janvier Labs)

第八章调查方法

Product Code: BHL3200SA

This report can be delivered within 1 working day.

Introduction of Transgenic Animal Model

The transgenic animal model market is experiencing significant growth, driven by advancements in genetic engineering and the increasing need for precise preclinical testing. Transgenic animals, modified to carry genes from other species, are crucial for studying human diseases, testing new therapies, and improving agricultural practices. These models help researchers simulate human diseases, providing insights into disease mechanisms, genetic predispositions, and the effects of potential treatments.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$2,796.0 Million
2035 Forecast$6,799.3 Million
CAGR9.29%

As the field of precision medicine evolves, transgenic models play a key role in advancing personalized healthcare. By enabling researchers to study genetic influences on diseases like cancer, inherited disorders, and chronic conditions, these models help create more targeted, effective treatments. With the rise of gene-editing technologies such as CRISPR-Cas9, the demand for these models is growing, supporting the development of therapies tailored to an individual's genetic makeup. The integration of these advanced models into research not only accelerates drug development but also improves patient outcomes by reducing the trial-and-error approach to treatment.

Market Introduction

The global transgenic animal model market is expected to witness substantial growth, projected to reach $6,799.3 million by 2035. The transgenic animal model market is witnessing substantial growth, fueled by advancements in genetic engineering and the increasing need for more accurate preclinical testing. Transgenic animal models, created by inserting foreign genes into an organism's genome, play a crucial role in understanding complex diseases and testing new therapeutic interventions. These models enable researchers to simulate human diseases, providing insights into disease mechanisms, genetic influences, and the effects of various treatments.

The growing demand for personalized medicine is driving the adoption of transgenic models, as they allow for a deeper understanding of how genetic factors contribute to individual disease susceptibility and treatment response. Technologies like CRISPR and next-generation sequencing (NGS) are accelerating the development of these models by enabling more precise genetic modifications, facilitating the creation of more accurate and human-like models. This is particularly important in areas such as oncology, neurology, and genetic disorders, where personalized treatments are gaining prominence.

Moreover, the integration of artificial intelligence (AI) and big data analytics is transforming how transgenic models are used in research. These technologies enhance the efficiency of drug development processes by predicting disease outcomes, optimizing treatment strategies, and improving the precision of animal models. As these technologies continue to evolve, they will drive further innovation in the transgenic animal model market, enabling more tailored and effective therapeutic solutions. However, challenges such as ethical concerns, regulatory complexities, and the high cost of creating and maintaining these models continue to impact the market's growth. Despite these hurdles, the continued advancements in gene-editing technologies and computational tools are expected to fuel the future expansion of the market.

Industrial Impact

Transgenic animal models are significantly impacting the biotechnology and pharmaceutical industries by advancing drug discovery and development. For example, the use of transgenic mice in Alzheimer's research has provided valuable insights into the disease's genetic underpinnings, leading to the testing of potential therapies like the amyloid-beta-targeting drug Aduhelm. These models help researchers simulate human diseases accurately, enabling more effective preclinical testing.

In clinical trials, transgenic models improve predictability and efficiency. For instance, genetically modified mice with human cancer genes have been used to test immunotherapies like Kymriah, a CAR-T therapy developed for leukemia. By mimicking human responses, these models reduce the risk of failure in later trial stages.

The use of CRISPR technology has enhanced transgenic animal models, allowing precise gene edits. This is particularly evident in research related to sickle cell disease, where transgenic mice have been used to test gene therapies, providing a path for treatments like CTX001, which is currently in clinical trials for sickle cell anemia.

Overall, transgenic models are accelerating precision medicine, improving therapeutic efficacy, and optimizing clinical trials, leading to faster, more cost-effective drug development.

Market Segmentation:

Segmentation 1: By Technology

  • CRISPR/CAS-9
  • Microinjections
  • Embryonic Stem Cell Injections
  • Others

In the global transgenic animal model market, as of 2024, the CRISPR/CAS9 segment holds the largest share at 44.96%. CRISPR/Cas9 has revolutionized the transgenic animal model market due to its precision, efficiency, and versatility in genetic modifications. Unlike traditional methods, CRISPR allows for precise gene knock-ins, knockouts, and edits at specific locations in the genome, making it faster, more accurate, and cost-effective. This has significantly accelerated the creation of animal models used in disease research, drug discovery, and personalized medicine. For example, CRISPR has enabled the development of genetically modified mice to model complex diseases like cancer, genetic disorders, and neurodegenerative diseases, which can be used to test targeted therapies and gene-editing treatments.

The rapid growth of the CRISPR/Cas9 market is driven by its ability to generate complex animal models quickly and at a lower cost compared to traditional methods. Its applications in areas such as gene therapy, cancer research, and personalized medicine are expanding, as companies and research institutions use CRISPR to create more accurate models for drug testing and therapeutic development. As the technology continues to advance, with improvements in precision and delivery, CRISPR is expected to further accelerate the pace of biomedical innovation, making it the dominant tool in genetic research and driving its fastest growth in the transgenic animal model market.

Segmentation 2: By Animal Type

  • Rodent (Mice & Rats)
  • Rabbits
  • Pigs
  • Others

Based on animal type, the global transgenic animal model market was led by the rodent segment, which held a 74.96% share in 2024. Rodents, particularly mice, dominate the transgenic animal model market, with over 95% of transgenic animals used in biomedical research being rodents. The mouse is the model organism of choice due to several key advantages: the extensive analysis of its completed genome sequence and its genetic similarity to humans. These factors make mice ideal for studying human diseases, genetic disorders, and drug responses. For instance, genetically modified mice are extensively used to model Alzheimer's disease, enabling the study of amyloid plaques and the testing of therapies like Aduhelm, a drug aimed at reducing plaque buildup. Mice are also commonly used in cancer research, where genes like p53 are knocked out to create models mimicking human tumor growth, facilitating the evaluation of treatments such as CAR-T cell therapy.

The growth of the rodent-based transgenic animal model market is driven by the mouse's ability to undergo precise genetic manipulation, supported by robust and sophisticated techniques. This allows researchers to replicate human diseases with high accuracy. Additionally, mice's short reproduction cycle, ability to perform physiologic and behavioral tests, and their adaptability to controlled laboratory environments make them perfect for large-scale studies. These characteristics, combined with their established role in studying diseases like cancer, neurodegenerative disorders, and metabolic diseases, ensure their continued dominance and rapid growth in the transgenic animal model market.

Segmentation 3: By Application

  • Drug Discovery and Development
  • Disease Research
  • Gene Function Studies
  • Toxicology and Safety Testing
  • Others

Based on application type, the drug discovery and development segment dominated the global transgenic animal model market with 54.19% share in 2024 because it is the primary user segment that applies these models across the full preclinical workflow from target validation and MoA studies to efficacy screening and early safety. Pharmaceutical and large biotechnology companies continue to allocate higher budgets to transgenic and humanized models, particularly for oncology, metabolic disorders, neurodegenerative diseases, and advanced modalities (immuno-oncology, gene and cell therapies), as these models improve translational relevance and help lower late-stage failure risk.Moreover, this segment also operates at higher study volumes and requires continuous access to licensed or custom-bred strains, which drives recurring spend. The availability of CRO-delivered, transgenic model services tailored to pharma pipelines has further streamlined adoption and reinforced demand. As a result, the drug discovery and development segment remains the largest and most commercially significant demand center in this market.

Segmentation 4: By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)

Based on end user type, the pharmaceutical and biotechnology companies dominated the global transgenic animal model market with 57.38% share in 2024. Pharmaceutical and biotechnology companies are the principal demand centers for transgenic animal models, and their R&D activity is the single largest contributor to market expansion. These organizations rely on genetically engineered animals to de-risk development - validating drug targets, interrogating disease pathways, generating efficacy and safety data, and refining dose regimens prior to first-in-human studies. In oncology, for instance, humanized transgenic mice are routinely used to evaluate immuno-oncology candidates, while larger transgenic species such as rabbits and pigs support cardiovascular and metabolic programs where physiology closer to humans is required. The accelerating shift toward precision medicine, biologics, and gene and cell therapies has amplified this need, because these modalities often target human-specific pathways that cannot be modeled adequately in vitro. At the same time, leading pharma players are commissioning bespoke transgenic lines to mirror rare, multifactorial, or pediatric diseases, thereby improving the probability of clinical success and meeting regulatory expectations for disease-relevant preclinical evidence. Together, factors such as sophisticated technology use, demand for translationally credible data, and tighter regulatory scrutiny position pharma and biotech companies as the core engines of growth and innovation in the transgenic animal model market.

Segmentation 5: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

North America maintains a dominant position in the transgenic animal model market due to several structural advantages. The region is home to the largest concentration of biopharma R&D activity, supported by a robust regulatory environment that fosters innovation. A significant number of U.S. and Canadian pharmaceutical and biotechnology companies are driving high-throughput preclinical pipelines in key therapeutic areas such as oncology, infectious disease, and metabolic disorders fields where transgenic and humanized animal models are essential for generating reliable in vivo data prior to clinical trials. Regulatory agencies like the FDA and Health Canada actively engage with emerging therapeutic modalities, including mRNA, personalized cancer vaccines, and RSV vaccines, which has spurred demand for more predictive animal models that meet stringent evidentiary standards. Additionally, North America's investment in manufacturing infrastructure, automation, and GMP-compliant workflows extends to preclinical operations, allowing for the rapid creation and deployment of custom transgenic lines, including disease-specific and humanized models.

The region's high burden of chronic diseases, coupled with its early adoption of precision medicine and cell/gene therapies, further drives the need for animal models that replicate human biological pathways. This convergence of strong capital availability, a dense ecosystem of contract research organizations (CROs), and a regulator-driven push for higher-quality data positions North America as the strategic epicenter of the transgenic animal model market.

Recent Developments in the Transgenic Animal Model Market

  • In August 2025, Taconic Biosciences, collaborated with Cyagen Biosciences to offer preclinical researchers broader and more streamlined access to Cyagen's extensive library of over 16,000 genetically engineered mouse models.
  • In July 2025, Biocytogen Pharmaceuticals announced a major upgrade to its preclinical business division. The enhancement includes a broadened range of genetically engineered animal models such as target-humanized, immune-humanized, transgenic, and immunodeficient mice along with comprehensive preclinical services, including efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing.
  • In October 2024, Alloy Therapeutics entered into an institutional licensing agreement with Scripps Research for its ATX-Gx platform, which enables fully human antibody discovery. This non-exclusive license allows all Scripps Research scientists to use the ATX-Gx platform in their antibody drug and vaccine development efforts
  • In June 2024, Biocytogen received a U.S. patent for its RenLite platform, which enables the creation of fully human antibodies with a common light chain, thereby simplifying the development of bispecific antibodies and ADCs. This innovation enhances antibody diversity and simplifies CMC processes.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers: Growing Number of Pharmaceutical Research and Drug Development Activities

The growing focus on pharmaceutical research and drug development is a key driver for the transgenic animal model market. As the industry shifts toward more targeted and effective therapies, the demand for transgenic animals has significantly increased. These genetically modified models are essential for addressing the complexities of modern drug development, especially in fields like personalized medicine and precision therapies. Transgenic animals simulate human disease biology, enabling researchers to test treatments in environments that closely resemble human conditions. For instance, humanized mice are used in HIV research to evaluate antiretroviral drugs before clinical trials.

With the pharmaceutical industry pushing for faster, more accurate drug discovery, the need for models that predict human responses has intensified. Transgenic animal models are critical for studying diseases that traditional models cannot replicate, such as cancer, neurodegenerative diseases, and cardiovascular disorders. For example, p53 knockout mice are used in cancer research to investigate tumor progression and test therapies targeting mutated genes, while transgenic mice expressing human tau proteins help study Alzheimer's disease. The increased investment in innovative drug and biologic research further fuels the demand for these models, which are indispensable in understanding disease mechanisms, testing new compounds, and assessing the safety and efficacy of treatments.

Market Challenges: High Maintenance Cost of Animal Models

High maintenance costs represent a major challenge in the transgenic animal model market. The development and upkeep of these models require significant financial investment at every stage, from breeding to experimental use. Specialized facilities with controlled environments are needed to house the animals, driving up capital and operational expenses compared to conventional models. Transgenic animals also demand advanced genetic engineering, continuous monitoring, and often multiple breeding generations, which extends timelines and increases labor costs for skilled professionals like geneticists and veterinarians.

For example, maintaining inbred C57BL/6 mice can cost upwards of $3,500 for animal purchase alone, excluding additional expenses for cage upkeep, veterinary care, and specialized procedures like microinjections or embryo transfers. These genetically modified animals require pathogen-free conditions and expert care, adding further to ongoing costs. While hybrid strains can lower some expenses, the overall financial burden of creating and maintaining transgenic models is prohibitive for smaller labs or startups, limiting market growth.

As a result, larger pharmaceutical companies like Pfizer or Novartis can afford the high costs for research, but smaller biotech firms and academic labs often turn to alternative models, such as cell-based assays or computational simulations. This financial barrier slows the market's expansion, especially among smaller players.

Market Opportunities: Emergence of CRISPR as a Powerful Tool for Biomedical Research Field

The emergence of CRISPR technology has revolutionized the creation and utility of transgenic animal models in biomedical research by enabling rapid, precise, and efficient genome editing. CRISPR/Cas9 allows researchers to generate targeted gene knockouts, knock-ins, and point mutations in animals ranging from mice to large species such as pigs, sheep, and chickens with much higher accuracy and lower cost compared to older methods such as homologous recombination in embryonic stem cells. CRISPR accelerates the development of disease models that closely mimic human pathologies, such as neurodegenerative disorders, cardiovascular disease, cystic fibrosis, and cancer, in animals large and small. These models help elucidate disease mechanisms and screen therapies more reliably. It enables complex genetic manipulations, including simultaneous editing of multiple genes, creating models for polygenic diseases or studying gene interactions.

CRISPR facilitates the production of bioreactor animals; for example, chickens engineered to produce pharmaceutical proteins in eggs or animals engineered for antibody manufacturing, which expands industrial and therapeutic applications. It allows the development of transgenic animals with disease resistance (e.g., virus-resistant poultry), supporting both food security and biomedical research.

Beyond gene editing, CRISPR is applied in regenerative medicine, tissue engineering, and epigenome editing, allowing the modulation of gene expression without changing DNA sequences. It is also employed in CRISPR-based diagnostic tools, such as SHERLOCK and DETECTR, which provide rapid and highly sensitive detection of viral infections and genetic mutations.

Market Trends: Rising Demand for Personalized Medicine

The growing emphasis on personalized medicine is significantly increasing demand for transgenic animal models, especially humanized mice, in drug discovery and therapeutic development. As treatments become more tailored to an individual's genetic profile, transgenic models are essential for testing gene therapies, immunotherapies, and patient-specific drug regimens. Humanized mouse models-engineered to express human genes or mutations-allow researchers to study human diseases with higher accuracy and predict treatment outcomes more effectively.

These models are crucial in gene-based therapies like antisense oligonucleotides (ASOs), used to silence harmful genes in neurodegenerative diseases such as Alzheimer's, Huntington's, and ALS. Successful studies in humanized mice have shown reduced disease-related gene expression and symptom improvement. Additionally, integrating CRISPR/Cas9 technology with transgenic models enables targeted gene correction, such as reducing hSOD1 levels in ALS mice to delay disease progression-paving the way for future gene-editing therapies.

Transgenic models also play a vital role in testing immunotherapies like CAR-T cells and antibody-based treatments that target human-specific proteins. For instance, humanized mice with human immune systems are used to evaluate immune responses in cancer and Alzheimer's research. Similarly, patient-derived xenograft (PDX) models-created by implanting human tumor tissues into mice-help assess how personalized therapies perform against a patient's unique genetic makeup.

As personalized medicine continues to evolve, transgenic animal models have become indispensable for developing genetically targeted therapies. They enable deeper insights into human disease diversity, streamline drug development, and support the creation of safer, more effective treatments tailored to individual patients.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in transgenic animal model, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new transgenic animal model products.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2021-FY2023 The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of CRISPR/CAS-9, Microinjections, Embryonic stem cell injections and other technology of the transgenic animal model market.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available transgenic animal model solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in transgenic animal model including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players of the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Charles River Laboratories International, Inc.
  • Creative Biolabs
  • Alloy Therapeutics, Inc.
  • Inotiv.
  • HuidaGene
  • genOway
  • Ingenious Targeting Laboratory
  • OmniAb Inc.
  • Taconic Biosciences
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd
  • Merck Group
  • Janvier Group

Table of Contents

Executive Summary

Scope and Definition

1 Global Transgenic Animal Model Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Market Overview and Ecosystem
  • 1.2 Market Trends
    • 1.2.1 Impact Analysis
    • 1.2.2 Rising Demand for Personalized Medicine
  • 1.3 Regulatory Landscape
    • 1.3.1 North America
      • 1.3.1.1 U.S.
    • 1.3.2 Europe
      • 1.3.2.1 Germany
      • 1.3.2.2 U.K.
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
    • 1.3.4 Rest-of-the-World
  • 1.4 Pricing Analysis
    • 1.4.1 Generation Costs (Creating New Models)
    • 1.4.2 Acquisition Costs (Purchasing Existing Models)
    • 1.4.3 Additional Costs
  • 1.5 Technology Landscape
  • 1.6 Market Dynamics
    • 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.6.2 Market Drivers
      • 1.6.2.1 Growing Number of Pharmaceutical Research and Drug Development Activities
      • 1.6.2.2 Technological Advancements in Genetic Engineering
      • 1.6.2.3 Increasing Demand for Advanced Disease Models for Drug Discovery
    • 1.6.3 Market Restraints
      • 1.6.3.1 High Maintenance Cost of Animal Models
      • 1.6.3.2 Strict Regulations and Guidelines
    • 1.6.4 Market Opportunities
      • 1.6.4.1 Emergence of CRISPR as a Powerful Tool for Biomedical Research Field
      • 1.6.4.2 Increasing Demand for Disease-Specific Models

2 Technology

  • 2.1 Overview
    • 2.1.1 CRISPR/Cas9
    • 2.1.2 Microinjection
    • 2.1.3 Embryonic Stem Cell Injections
    • 2.1.4 Other Technologies

3 Animal Type

  • 3.1 Overview
    • 3.1.1 Rodents (Mice and Rats)
    • 3.1.2 Rabbits
    • 3.1.3 Pigs
    • 3.1.4 Other Animal Types

4 Application

  • 4.1 Overview
    • 4.1.1 Drug Discovery and Development
    • 4.1.2 Disease Research
    • 4.1.3 Gene Function Studies
    • 4.1.4 Toxicology and Safety Testing
    • 4.1.5 Other Applications

5 End User

  • 5.1 Overview
    • 5.1.1 Pharmaceutical and Biotechnology Companies
    • 5.1.2 Contract Research Organizations (CROs)
    • 5.1.3 Academic and Research Institutes

6 Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Market Sizing and Forecast
      • 6.2.4.1 North America Transgenic Animal Model Market, by Technology
      • 6.2.4.2 North America Transgenic Animal Model Market, by Animal Type
      • 6.2.4.3 North America Transgenic Animal Model Market, by Application
      • 6.2.4.4 North America Transgenic Animal Model Market, by End User
      • 6.2.4.5 North America Transgenic Animal Model Market, by Country
    • 6.2.5 U.S.
      • 6.2.5.1 Country Overview
      • 6.2.5.2 U.S. Transgenic Animal Model Market, by Technology
      • 6.2.5.3 U.S. Transgenic Animal Model Market, by Animal Type
      • 6.2.5.4 U.S. Transgenic Animal Model Market, by Application
      • 6.2.5.5 U.S. Transgenic Animal Model Market, by End User
    • 6.2.6 Canada
      • 6.2.6.1 Country Overview
      • 6.2.6.2 Canada Transgenic Animal Model Market, by Technology
      • 6.2.6.3 Canada Transgenic Animal Model Market, by Animal Type
      • 6.2.6.4 Canada Transgenic Animal Model Market, by Application
      • 6.2.6.5 Canada Transgenic Animal Model Market, by End User
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Market Sizing and Forecast
      • 6.3.4.1 Europe Transgenic Animal Model Market, by Technology
      • 6.3.4.2 Europe Transgenic Animal Model Market, by Animal Type
      • 6.3.4.3 Europe Transgenic Animal Model Market, by Application
      • 6.3.4.4 Europe Transgenic Animal Model Market, by End User
      • 6.3.4.5 Europe Transgenic Animal Model Market, by Country
    • 6.3.5 U.K.
      • 6.3.5.1 Country Overview
      • 6.3.5.2 U.K. Transgenic Animal Model Market, by Technology
      • 6.3.5.3 U.K. Transgenic Animal Model Market, by Animal Type
      • 6.3.5.4 U.K. Transgenic Animal Model Market, by Application
      • 6.3.5.5 U.K. Transgenic Animal Model Market, by End User
    • 6.3.6 Germany
      • 6.3.6.1 Country Overview
      • 6.3.6.2 Germany Transgenic Animal Model Market, by Technology
      • 6.3.6.3 Germany Transgenic Animal Model Market, by Animal Type
      • 6.3.6.4 Germany Transgenic Animal Model Market, by Application
      • 6.3.6.5 Germany Transgenic Animal Model Market, by End User
    • 6.3.7 France
      • 6.3.7.1 Country Overview
      • 6.3.7.2 France Transgenic Animal Model Market, by Technology
      • 6.3.7.3 France Transgenic Animal Model Market, by Animal Type
      • 6.3.7.4 France Transgenic Animal Model Market, by Application
      • 6.3.7.5 France Transgenic Animal Model Market, by End User
    • 6.3.8 Italy
      • 6.3.8.1 Country Overview
      • 6.3.8.2 Italy Transgenic Animal Model Market, by Technology
      • 6.3.8.3 Italy Transgenic Animal Model Market, by Animal Type
      • 6.3.8.4 Italy Transgenic Animal Model Market, by Application
      • 6.3.8.5 Italy Transgenic Animal Model Market, by End User
    • 6.3.9 Spain
      • 6.3.9.1 Country Overview
      • 6.3.9.2 Spain Transgenic Animal Model Market, by Technology
      • 6.3.9.3 Spain Transgenic Animal Model Market, by Animal Type
      • 6.3.9.4 Spain Transgenic Animal Model Market, by Application
      • 6.3.9.5 Spain Transgenic Animal Model Market, by End User
    • 6.3.10 Rest-of-the- Europe
      • 6.3.10.1 Country Overview
      • 6.3.10.2 Rest of the Europe Transgenic Animal Model Market, by Technology
      • 6.3.10.3 Rest of the Europe Transgenic Animal Model Market, by Animal Type
      • 6.3.10.4 Rest of the Europe Transgenic Animal Model Market, by Application
      • 6.3.10.5 Rest of the Europe Transgenic Animal Model Market, by End User
  • 6.4 Asia Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Market Sizing and Forecast
      • 6.4.4.1 Asia Pacific Transgenic Animal Model Market, by Technology
      • 6.4.4.2 Asia Pacific Transgenic Animal Model Market, by Animal Type
      • 6.4.4.3 Asia Pacific Transgenic Animal Model Market, by Application
      • 6.4.4.4 Asia Pacific Transgenic Animal Model Market, by End User
      • 6.4.4.5 Asia PacificTransgenic Animal Model Market, by Country
    • 6.4.5 China
      • 6.4.5.1 Country Overview
      • 6.4.5.2 China Transgenic Animal Model Market, by Technology
      • 6.4.5.3 China Transgenic Animal Model Market, by Animal Type
      • 6.4.5.4 China Transgenic Animal Model Market, by Application
      • 6.4.5.5 China Transgenic Animal Model Market, by End User
    • 6.4.6 Japan
      • 6.4.6.1 Country Overview
      • 6.4.6.2 Japan Transgenic Animal Model Market, by Technology
      • 6.4.6.3 Japan Transgenic Animal Model Market, by Animal Type
      • 6.4.6.4 Japan Transgenic Animal Model Market, by Application
      • 6.4.6.5 Japan Transgenic Animal Model Market, by End User
    • 6.4.7 India
      • 6.4.7.1 Country Overview
      • 6.4.7.2 India Transgenic Animal Model Market, by Technology
      • 6.4.7.3 India Transgenic Animal Model Market, by Animal Type
      • 6.4.7.4 India Transgenic Animal Model Market, by Application
      • 6.4.7.5 India Transgenic Animal Model Market, by End User
    • 6.4.8 Australia
      • 6.4.8.1 Country Overview
      • 6.4.8.2 Australia Transgenic Animal Model Market, by Technology
      • 6.4.8.3 Australia Transgenic Animal Model Market, by Animal Type
      • 6.4.8.4 Australia Transgenic Animal Model Market, by Application
      • 6.4.8.5 Australia Transgenic Animal Model Market, by End User
    • 6.4.9 South Korea
      • 6.4.9.1 Country Overview
      • 6.4.9.2 South Korea Transgenic Animal Model Market, by Technology
      • 6.4.9.3 South Korea Transgenic Animal Model Market, by Animal Type
      • 6.4.9.4 South Korea Transgenic Animal Model Market, by Application
      • 6.4.9.5 South Korea Transgenic Animal Model Market, by End User
    • 6.4.10 Rest-of-the- Asia Pacific
      • 6.4.10.1 Country Overview
      • 6.4.10.2 Rest of the Asia Pacific Transgenic Animal Model Market, by Technology
      • 6.4.10.3 Rest of the Asia Pacific Transgenic Animal Model Market, by Animal Type
      • 6.4.10.4 Rest of the Asia Pacific Transgenic Animal Model Market, by Application
      • 6.4.10.5 Rest of the Asia Pacific Transgenic Animal Model Market, by End User
  • 6.5 Rest of the World
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
    • 6.5.4 Market Sizing and Forecast
      • 6.5.4.1 Rest of the World Transgenic Animal Model Market, by Technology
      • 6.5.4.2 Rest of the World Transgenic Animal Model Market, by Animal Type
      • 6.5.4.3 Rest of the World Transgenic Animal Model Market, by Application
      • 6.5.4.4 Rest of the World Transgenic Animal Model Market, by End User

7 Competitive Benchmarking and Company Profiles

  • 7.1 Key Strategies and Developments, 2023-2025
  • 7.2 Key Developments Analysis, by Company, 2023-2025
  • 7.3 Company Profiles
    • 7.3.1 Charles River Laboratories International, Inc.
      • 7.3.1.1 Overview
    • 7.3.2 Creative Biolabs
      • 7.3.2.1 Overview
    • 7.3.3 Alloy Therapeutics, Inc.
      • 7.3.3.1 Overview
    • 7.3.4 Inotiv.
      • 7.3.4.1 Overview
    • 7.3.5 Ingenious Targeting Laboratory.
      • 7.3.5.1 Overview
    • 7.3.6 HuidaGene
      • 7.3.6.1 Overview
    • 7.3.7 genOway
      • 7.3.7.1 Overview
    • 7.3.8 OmniAb, Inc.
      • 7.3.8.1 Overview
    • 7.3.9 Taconic Biosciences
      • 7.3.9.1 Overview
    • 7.3.10 Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'
      • 7.3.10.1 Overview
    • 7.3.11 Sigma-Aldrich Co. (Merck Group)
      • 7.3.11.1 Overview
    • 7.3.12 Janvier Group (Janvier Labs)
      • 7.3.12.1 Overview

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Inclusion and Exclusion
    • 8.1.4 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Transgenic Animal Model Market (by Scenario), $Million, 2024, 2028, and 2035
  • Figure 2: Global Transgenic Animal Model Market, 2024 and 2035
  • Figure 3: Top Countries, Global Transgenic Animal Model Market, $Million, 2024
  • Figure 4: Global Transgenic Animal Model Market Snapshot
  • Figure 5: Global Transgenic Animal Model Market, $Million, 2024 and 2035
  • Figure 6: Transgenic Animal Model Market (by Technology), $Million, 2024, 2028, and 2035
  • Figure 7: Transgenic Animal Model Market (by Animal Type), $Million, 2024, 2028, and 2035
  • Figure 8: Transgenic Animal Model Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 9: Transgenic Animal Model Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 10: Transgenic Animal Model Market Segmentation
  • Figure 11: Key Stakeholders of Transgenic Animal Model Market
  • Figure 12: Transgenic Animals: Timeline of Key Events
  • Figure 13: Role of Humanized Mouse Models in Development of New Precision and Personalized Medicine Strategies
  • Figure 14: Regulatory Bodies of Transgenic Animals in Europe
  • Figure 15: Regulatory Bodies of Transgenic Animals in Germany
  • Figure 16: Regulatory Process
  • Figure 17: Evolution of Transgenic Technologies
  • Figure 18: Global Drug Development Pipeline, 2019 and 2024
  • Figure 19: Major Technical Advances in Genome Editing and Delivery in Mice and Rats from 1980s to 2020s
  • Figure 20: Global Transgenic Animal Model Market (by Technology), $Million, 2024, 2028, and 2035
  • Figure 21: Transgenic Animal Model Market, CRISPR/Cas9, $Million, 2024-2035
  • Figure 22: Transgenic Animal Model Market, Microinjection, $Million, 2024-2035
  • Figure 23: Transgenic Animal Model Market, Embryonic Stem Cell Injections, $Million, 2024-2035
  • Figure 24: Transgenic Animal Model Market, Other Technologies, $Million, 2024-2035
  • Figure 25: Global Transgenic Animal Model Market (by Animal Type), $Million, 2024, 2028, and 2035
  • Figure 26: Transgenic Animal Model Market, Rodents (Mice and Rats), $Million, 2024-2035
  • Figure 27: Transgenic Animal Model Market, Rabbits, $Million, 2024-2035
  • Figure 28: Transgenic Animal Model Market, Pigs, $Million, 2024-2035
  • Figure 29: Transgenic Animal Model Market, Other Animal Types, $Million, 2024-2035
  • Figure 30: Global Transgenic Animal Model Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 31: Transgenic Animal Model Market, Drug Discovery and Development, $Million, 2024-2035
  • Figure 32: Transgenic Animal Model Market, Disease Research, $Million, 2024-2035
  • Figure 33: Transgenic Animal Model Market, Gene Function Studies, $Million, 2024-2035
  • Figure 34: Transgenic Animal Model Market, Toxicology and Safety Testing, $Million, 2024-2035
  • Figure 35: Transgenic Animal Model Market, Other Applications, $Million, 2024-2035
  • Figure 36: Global Transgenic Animal Model Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 37: Transgenic Animal Model Market, Pharmaceutical and Biotechnology Companies, $Million, 2024-2035
  • Figure 38: Transgenic Animal Model Market, Contract Research Organizations (CROs), $Million, 2024-2035
  • Figure 39: Transgenic Animal Model Market, Academic and Research Institutes, $Million, 2024-2035
  • Figure 40: North America Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 41: Europe Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 42: Asia Pacific Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 43: Rest of the World Transgenic Animal Model Market, $Million, 2024-2035
  • Figure 44: Key Strategies and Developments, 2023-2025
  • Figure 45: Inclusion and Exclusion Criteria for Global Transgenic Animal Model Market
  • Figure 46: Data Triangulation
  • Figure 47: Top-Down and Bottom-Up Approach
  • Figure 48: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Cost of Generating New Transgenic Animals
  • Table 3: Cost of Purchasing Existing Models
  • Table 4: Additional Costs
  • Table 5: Global Transgenic Animal Model Market (by Region), $Million, 2024-2035
  • Table 6: Transgenic Animal Model Market (by Region), $Million, 2024-2035
  • Table 7: North America Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 8: North America Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 9: North America Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 10: North America Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 11: North America Transgenic Animal Model Market (by Country), $Million, 2024-2035
  • Table 12: U.S. Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 13: U.S. Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 14: U.S. Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 15: U.S. Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 16: Canada Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 17: Canada Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 18: Canada Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 19: Canada Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 20: Europe Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 21: Europe Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 22: Europe Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 23: Europe Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 24: Europe Transgenic Animal Model Market (by Country), $Million, 2024-2035
  • Table 25: U.K. Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 26: U.K. Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 27: U.K. Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 28: U.K. Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 29: Germany Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 30: Germany Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 31: Germany Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 32: Germany Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 33: France Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 34: France Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 35: France Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 36: France Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 37: Italy Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 38: Italy Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 39: Italy Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 40: Italy Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 41: Spain Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 42: Spain Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 43: Spain Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 44: Spain Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 45: Rest of the Europe Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 46: Rest of the Europe Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 47: Rest of the Europe Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 48: Rest of the Europe Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 49: Asia Pacific Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 50: Asia Pacific Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 51: Asia Pacific Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 52: Asia Pacific Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 53: Asia Pacific Transgenic Animal Model Market (by Country), $Million, 2024-2035
  • Table 54: China Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 55: China Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 56: China Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 57: China Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 58: Japan Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 59: Japan Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 60: Japan Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 61: Japan Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 62: India Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 63: India Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 64: India Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 65: India Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 66: Australia Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 67: Australia Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 68: Australia Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 69: Australia Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 70: South Korea Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 71: South Korea Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 72: South Korea Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 73: South Korea Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 74: Rest of the Asia Pacific Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 75: Rest of the Asia Pacific Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 76: Rest of the Asia Pacific Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 77: Rest of the Asia Pacific Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 78: Rest of the World Transgenic Animal Model Market (by Technology), $Million, 2024-2035
  • Table 79: Rest of the World Transgenic Animal Model Market (by Animal Type), $Million, 2024-2035
  • Table 80: Rest of the World Transgenic Animal Model Market (by Application), $Million, 2024-2035
  • Table 81: Rest of the World Transgenic Animal Model Market (by End User), $Million, 2024-2035
  • Table 82: Key Strategies and Developments, 2023-2025